Overview
Updated 14 Jul 2026
Mark Genovese, MD, is Senior Vice President, Immunology Development, Eli Lilly and Company. The public record shows 440 publications with 33,650 citations (h-index 90), centered on Psoriasis / Psoriatic Arthritis, Rheumatoid Arthritis, Osteoarthritis. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 2 companies, 1 NIH-funded awards (2005–2008).
- Most recent indexed publication: 2026 · Arthritis & rheumatology (Hoboken, N.J.)
- Top research focus: Psoriasis / Psoriatic Arthritis
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 31 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)
Sponsor: SetPoint Medical Corporation
InvestigatorCompletedNCT03437473 - A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
Sponsor: AbGenomics B.V Taiwan Branch
InvestigatorPhase 2CompletedNCT02267642 - Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056
Sponsor: UCB BIOSCIENCES, Inc.
InvestigatorPhase 2TerminatedNCT01296711
Industry payments
Updated 14 Jul 2026
2 companies reported payments to CMS in program years 2022–2025. These are public disclosures, not judgments. The latest:
- Eli Lilly and CompanyProgram year20251 payment
- Eli Lilly and CompanyProgram year20237 payments
- Gilead Sciences, Inc.Program year20221 payment
NIH funding
Updated 14 Jul 2026
1 NIH research award on record, funded 2005–2008 per NIH RePORTER. The latest:
- CLINICAL TRIAL: RITUXIMAB WITH OR WITHOUT METHOTREX IN PSORIATIC ARTHRITIS AND P
Stanford University
FY2008$2,276M01RR000070 - FONTOLIZUMAB IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS
Stanford University
FY2007$14,044M01RR000070 - TUMOR NECROSIS FACTOR-ALPHA INHIBITION (ADALIMUMAB) IN OSTEOARTHRITIS
Stanford University
FY2007$5,851M01RR000070
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity.
Arthritis & rheumatology (Hoboken, N.J.)
2026 - A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis.
Arthritis & rheumatology (Hoboken, N.J.)
2023 - Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives.
Patient preference and adherence
2023
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
900 Blake Wilbur Dr, Rm W2081, 2nd Floor, Stanford, CA 94305
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu ↗
- B.A.
University of Notre Dame
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu ↗
Editorial & leadership rolesjournal and society appointments
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →prnewswire.com ↗
- Director
Rheumatology Clinic, Division of Immunology and Rheumatology, Stanford University Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu ↗
Secondary affiliationsappointments beyond the home institution
- James W. Raitt
M.D. Professor of Medicine, Emeritus (Active), Division of Immunology and Rheumatology, Stanford University Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Media & interviewspress, podcasts and appearances
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗
- Q&A on IBD/GI pipeline as Lilly SVP
Pharmaceutical Executive
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pharmexec.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.